First Time Loading...

Concert Pharmaceuticals Inc
NASDAQ:CNCE

Watchlist Manager
Concert Pharmaceuticals Inc Logo
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Watchlist
Price: 8.37 USD Market Closed
Updated: Jun 3, 2024

Concert Pharmaceuticals Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Concert Pharmaceuticals Inc
Total Current Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Total Current Liabilities
$16.1m
CAGR 3-Years
23%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$41.5B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$13B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
8%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$19.7B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$3.8B
CAGR 3-Years
25%
CAGR 5-Years
28%
CAGR 10-Years
26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.6B
CAGR 3-Years
4%
CAGR 5-Years
19%
CAGR 10-Years
28%

See Also

What is Concert Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
16.1m USD

Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Total Current Liabilities amounts to 16.1m USD.

What is Concert Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
24%

Over the last year, the Total Current Liabilities growth was 58%. The average annual Total Current Liabilities growth rates for Concert Pharmaceuticals Inc have been 23% over the past three years , 24% over the past five years .